Adar T, et al. - In patients with inflammatory bowel diseases (IBD) >60 years of age, researchers assessed the safety and effectiveness of tumor necrosis factor α antagonist (anti-TNF) vs vedolizumab (VDZ). The study sample consisted of patients with Crohn's disease (CD) or ulcerative colitis (UC) ≥60 years of age starting anti-TNF or VDZ therapy at three study sites. This retrospective study involved 131 anti-TNF and 103 VDZ initiated patients. In elderly IBD patients, both anti-TNF and VDZ therapy were equally effective and safe. In both groups, pneumonia was the most common infection.